Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
News
BioAdvance Commits $3.2M to Life Sciences Companies in First Six Months of FY 2018
Investment Capabilities Expanded as Frederick (“Rick”) Jones, M.D., M.B.A., Joins Team
UCSF Medical Center selects Bainbridge Health to Support Its Continued Commitment to Medication Safety
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
VenatoRx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens
Servier and Treventis begin strategic research partnership in neurodegenerative diseases
VenatoRx Pharmaceuticals Receives FDA’s QIDP and Fast Track Designations for Development of its Lead Antibiotic Program
Jenrin Discovery’s IND Application for Its Peripherally Restricted Cannabinoid-1 Receptor Inverse Agonist NASH Compound Was Cleared by the FDA to Begin Phase 1 Clinical Trials